A new enzyme treatment for pancreatic insufficiency
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study tests a new pancreatic enzyme medicine (called NHS7108) for people with exocrine pancreatic insufficiency (EPI). EPI means your pancreas doesn't make enough enzymes to break down food properly. The study aims to see if this new medicine is safe and works well to help your body absorb nutrients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have long-standing (not just temporary) exocrine pancreatic insufficiency (EPI), meaning your body doesn't make enough digestive enzymes.
- You are currently taking pancreatic enzyme replacement therapy (PERT) or would need it.
- You have a body mass index (BMI) between 17 and 35 (within a healthy range).
- You have not had major stomach or intestinal surgery (with a few exceptions, like appendix removal).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (ANG003) for people with cystic fibrosis who have severe pancreatic problems. It looks at how safe and effective the medicine is, and whether it helps with digestion.
This trial tests whether enzymes from microbes work as well as enzymes from pigs to help people with chronic pancreatitis digest food better. It aims to find a treatment that reduces symptoms like pain and poor digestion.
This study tests whether the RELiZORB device (which helps digest fat in tube feedings) can improve symptoms for patients with pancreatitis and pancreatic enzyme insufficiency who are in the hospital and rely on a feeding tube for most of their nutrition.
This study follows people with certain inflammatory or cyst-related pancreas conditions to learn more about their health and outcomes. It may help improve understanding of these pancreas problems and guide better care.
This trial is testing a new navigation system to help doctors see the pancreas during an endoscopic ultrasound (EUS) exam. The system may make it easier to spot lesions or other problems in the pancreas.
This trial tests a new drug called nuzefatide pevedotin for people with metastatic pancreatic cancer that has progressed after one prior treatment. The drug targets a protein called EphA2 found on some tumor cells and may slow tumor growth.
Hear when a new Pancreatic Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.